Interim Report April - June 2025
Regulatory
A strong start to the year - Sales and operating profit growing, good progress in business development
Welcome to EQL Pharma's Investor Pages!
We strive to have an open and proactive dialogue with our shareholders.
Read MoreInterim Report Q1 2025/2026
Listen to CEO Axel Schörling present EQL Pharma's latest report.
Interim Report Q1 2025/2026Press Releases
Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2025/26
EQL Pharma AB (publ) will publish its interim report for the first quarter, 2025/26, on Friday, August 8[th], before stock markets open.
Notice of annual general meeting in EQL Pharma AB
Regulatory
The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 21 August 2025 at 16.00 at the company’s premises at Stortorget 1 in...
EQL Pharma in Short
EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.
Read more about usFinancial Calendar
21Aug2025
Annual General Meeting 2025
05Nov2025
Interim Report Q2
03Feb2026
Interim Report Q3